Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab subcutaneous maintenance therapy in moderately to severely active ulcerative colitis
NL-OMON43689Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in autoimmune colitis (3 arms), sponsored by Takeda. Primary endpoint: Clinical remission at Week 52. Started Sep 2016; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON43689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43689.